These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3375501)

  • 21. Interspecific scaling of toxicity data: a question of interpretation.
    Chappell WR
    Risk Anal; 1989 Mar; 9(1):13-4. PubMed ID: 2710971
    [No Abstract]   [Full Text] [Related]  

  • 22. Scaling laws for plasma concentrations and tolerable doses of anticancer drugs.
    Dawson TH
    Cancer Res; 2010 Jun; 70(12):4801-8. PubMed ID: 20530681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A global pharmaceutical company initiative: an evidence-based approach to define the upper limit of body weight loss in short term toxicity studies.
    Chapman K; Sewell F; Allais L; Delongeas JL; Donald E; Festag M; Kervyn S; Ockert D; Nogues V; Palmer H; Popovic M; Roosen W; Schoenmakers A; Somers K; Stark C; Stei P; Robinson S
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):27-38. PubMed ID: 23602904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Issues in carcinogenicity testing: dose selection.
    Haseman JK
    Fundam Appl Toxicol; 1985 Feb; 5(1):66-78. PubMed ID: 3886467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of preclinical toxicology studies for platinum anticancer drugs.
    Clark DL; Andrews PA; Smith DD; DeGeorge JJ; Justice RL; Beitz JG
    Clin Cancer Res; 1999 May; 5(5):1161-7. PubMed ID: 10353752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relevance of experimental studies to human risk.
    Dietz FK; Ramsey JC; Watanabe PG
    Environ Health Perspect; 1983 Oct; 52():9-14. PubMed ID: 6653541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).
    Giovanella BC; Stehlin JS; Hinz HR; Kozielski AJ; Harris NJ; Vardeman DM
    Int J Oncol; 2002 Jan; 20(1):81-8. PubMed ID: 11743646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosage regimen design for pharmaceutical studies conducted in animals.
    Mordenti J
    J Pharm Sci; 1986 Sep; 75(9):852-7. PubMed ID: 3465954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Translating dosages from animal models to human clinical trials--revisiting body surface area scaling.
    Blanchard OL; Smoliga JM
    FASEB J; 2015 May; 29(5):1629-34. PubMed ID: 25657112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome.
    Mirsalis JC; Schindler-Horvat J; Hill JR; Green CE; Mitoma C; Tomaszewski JE; Tyson CA; Donohue SJ
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):193-201. PubMed ID: 12655436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.
    Khor SP; Amyx H; Davis ST; Nelson D; Baccanari DP; Spector T
    Cancer Chemother Pharmacol; 1997; 39(3):233-8. PubMed ID: 8996526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.
    Schwartz J; Toste B; Dizon DS
    Gynecol Oncol; 2009 Jul; 114(1):53-6. PubMed ID: 19359030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological basis for extrapolation across mammalian species.
    Davidson IW; Parker JC; Beliles RP
    Regul Toxicol Pharmacol; 1986 Sep; 6(3):211-37. PubMed ID: 3775081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Animal toxicology for early clinical trials with anticancer agents.
    Rozencweig M; Von Hoff DD; Staquet MJ; Schein PS; Penta JS; Goldin A; Muggia FM; Freireich EJ; DeVita VT
    Cancer Clin Trials; 1981; 4(1):21-8. PubMed ID: 6783332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A method for determining the maximum tolerated dose for acute in vivo cytogenetic studies.
    Thompson ED; Gibson DP
    Food Chem Toxicol; 1984 Aug; 22(8):665-76. PubMed ID: 6540742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterizing interspecies uncertainty using data from studies of anti-neoplastic agents in animals and humans.
    Price PS; Keenan RE; Swartout JC
    Toxicol Appl Pharmacol; 2008 Nov; 233(1):64-70. PubMed ID: 18514247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment factors--applications in health risk assessment of chemicals.
    Falk-Filipsson A; Hanberg A; Victorin K; Warholm M; Wallén M
    Environ Res; 2007 May; 104(1):108-27. PubMed ID: 17166493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extrapolation of experimental data from animals to man.
    Krasovskii GN
    Environ Health Perspect; 1976 Feb; 13():51-8. PubMed ID: 817898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Use of body weight and body surface area in dosing of anticancer agents in adult patients].
    Levêque D
    Bull Cancer; 2007 Jul; 94(7):647-51. PubMed ID: 17723945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scaling respiratory pattern and respiratory 'drive'.
    Boggs DF; Tenney SM
    Respir Physiol; 1984 Dec; 58(3):245-51. PubMed ID: 6528102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.